CureVac (CVAC.US) stock fell sharply during today's session, after the biopharmaceutical company abandoned efforts to get its first generation drug approved by regulators. The decision came after the European Medicines Agency told the company it would not fast-track the approval process after clinical tests had shown it had only a 48% efficiency rate in preventing serious disease. CureVac plans to now focus on the development of second-generation COVID-19 vaccine candidates with its partner GlaxoSmithKline (GSK.US). CureVac and GSK aim to secure regulatory approval for market readiness of an improved Covid-19 vaccine in 2022. The companies also plan to accelerate efforts to progress the development of modified mRNA vaccine constructs.
CureVac (CVAC.US) stock launched today's session sharply lower, however buyers managed to partially erase early losses. However, only breaking above the resistance at $42.58 will invalidate the bearish scenario and the stock price may launch another upward impulse towards $52.85. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
